Example: stock market

ESCMID guideline: diagnosis and treatment of …

ORIGINAL ARTICLEESCMID guideline: diagnosis and treatment of acute bacterial meningitisD. van de Beek1, C. Cabellos2, O. Dzupova3, S. Esposito4, M. Klein5, A. T. Kloek1, S. L. Leib6, B. Mourvillier7, C. Ostergaard8,P. Pagliano9, , R. C. Read10, O. Resat Sipahi11and M. C. Brouwer1, for the ESCMID Study Group for Infections of theBrain (ESGIB)1)Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands,2)Department of Infectious Diseases, Hospital Universitari de Bellvitge,Barcelona, Spain,3)Department of Infectious Diseases, Charles University, Third Faculty of Medicine, Prague, Czech Republic,4)Pediatric Highly Intensive CareUnit, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universit degli Studi di Milano, Milan, Italy,5)Department of Neurol

Methods of guideline development Literature search. As preparation for this guideline development project, a search was performed for existing guidelines from

Tags:

  Guidelines, Treatment, Diagnosis, Escmid guideline, Escmid, Diagnosis and treatment

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of ESCMID guideline: diagnosis and treatment of …

1 ORIGINAL ARTICLEESCMID guideline: diagnosis and treatment of acute bacterial meningitisD. van de Beek1, C. Cabellos2, O. Dzupova3, S. Esposito4, M. Klein5, A. T. Kloek1, S. L. Leib6, B. Mourvillier7, C. Ostergaard8,P. Pagliano9, , R. C. Read10, O. Resat Sipahi11and M. C. Brouwer1, for the ESCMID Study Group for Infections of theBrain (ESGIB)1)Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands,2)Department of Infectious Diseases, Hospital Universitari de Bellvitge,Barcelona, Spain,3)Department of Infectious Diseases, Charles University, Third Faculty of Medicine, Prague, Czech Republic,4)Pediatric Highly Intensive CareUnit, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universit degli Studi di Milano, Milan, Italy,5)

2 Department of Neurology, KlinikumGro hadern, Munich, Germany,6)Institute for Infectious Diseases, University of Bern, Bern, Switzerland,7)Department of Intensive Care Medicine, GroupeHospitalier Bichat-Claude Bernard, Paris, France,8)Department of Clinical Microbiology, Copenhagen University Hospital Hvidovre, Hvidovre,Denmark,9)Department of Infectious Diseases, D. Cotugno Hospital, Naples, Italy,10)Department of Infectious Diseases, Southampton General Hospital,Southampton, United Kingdom and11)Department of Infectious Diseases and Clinical Microbiology, Ege University, Izmir, TurkeyKeywords:Antibiotic, bacterial meningitis, ESCMID , guideline,Neisseria meningitidis,Streptococcus pneumoniaeOriginal Submission:10 December 2015;Accepted:11 January 2016 Editor: D.

3 RaoultArticle published online:7 April 2016 Corresponding Brouwer, Department of Neurology,Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, introductionMotivation for guideline developmentBacterial meningitis is a severe infectious disease of the mem-branes lining the brain resulting in a high mortality and morbiditythroughout the world. In the past decades the epidemiology andtreatment strategies for community-acquired bacterial meningitishave significantly changed[1 3]. First, the introduction of con-jugate vaccines in Europe resulted in the virtual disappearance ofHaemophilus influenzaetype b, while conjugate pneumococcal andmeningococcal vaccines have substantially reduced the burden ofbacterial meningitis[1].

4 As a result, community-acquired bacterialmeningitis has become a disease that currently affects more adultsthan infants, with its specific complications and treatment secondimportant development isthe increasing rate of reducedsusceptibility to common antimicrobial agents among strains ofStreptococcus pneumoniae(pneumococcus) andNeisseria meningi-tidis(meningococcus). Large differences in resistance rates inEurope exist, and empiric antibiotic treatment needs to beadjusted according to regional epidemiology. Finally, severaladjunctive treatments have been tested in randomized controlledtrials, often with conflicting results[3].

5 These developments leavethe physician in need of a clear practical guideline, summarizingthe available evidence for diagnostic methods, and antimicrobialand adjunctive treatment in bacterial meningitis. To this end theEuropean Society for Clinical Microbiology and Infectious Dis-eases ( ESCMID ) promotes guidelines development in thefield ofinfectious diseases. This guideline project was initiated by theESCMID Study Group for Infections of the Brain (ESGIB).Aim of guidelineThe guideline is aimed at providing guidance in daily practice fordiagnosis and treatment of community-acquired bacterialmeningitis in hospitals.

6 The conclusions of the guideline provideup-to-date scientific evidence for best medical practice. Therecommendations are aimed at explicating this best medicalpractice and are based on available scientific evidence and theconsiderations of the guideline committee formulated ten key questions and severalsubquestions, which aim to address the full spectrum of currentclinical dilemmas in the diagnosis and treatment of community-acquired bacterial What are the causative microorganisms of community-acquired bacterial meningitis in specific groups (neonates,children, adults and immunocompromised patients)?

7 What are the clinical characteristics of community-acquiredbacterial meningitis, and what is their diagnostic accuracy?Clin Microbiol Infect2016;22:S37 S62 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights What is the diagnostic accuracy of algorithms in thedistinction between bacterial and viral meningitis?4. Can we use clinical characteristics to predict the absenceof intracranial abnormalities associated with increased riskof lumbar puncture? If lumbar puncture is delayed, should we start treatment ?

8 What is the optimal type, duration and method ofadministration of antibiotic treatment when startedempirically, after the pathogen has been identified or inculture-negative patients? Does the addition of vancomycin or rifampicin to a third-generation cephalosporin improve outcome inpneumococcal meningitis patients in the setting of a highresistance rate of pneumococci?6. Does dexamethasone have a beneficial effect on death,functional outcome and hearing loss in adults andchildren with bacterial meningitis?

9 Up to what point in time is treatment with dexamethasoneindicated if antibiotics are already provided? Should dexamethasone be stopped if pathogens otherthanS. pneumoniaeare identified?7. Do glycerol, mannitol, acetaminophen/paracetamol,hypothermia, antiepileptic drugs or hypertonic salinehave a beneficial effect on death, functional outcomeand hearing loss in adults and children with bacterialmeningitis?8. Does the use of prophylactic treatment of householdcontacts decrease carriage or secondary cases? Is vaccination indicated after community-acquired(pneumococcal) meningitis?

10 9. What complications occur during community-acquiredbacterial meningitis, what ancillary investigations arewarranted when complications occur and how shouldthey be treated? What follow-up of community-acquired bacterialmeningitis patients should be provided ( testing forhearing loss, neuropsychologic evaluation)?Meningococcal disease but also other bacterial infections canpresent with both meningitis and sepsis. This guideline is notaimed at the urgent recognition and treatment of sepsis pa-tients. Therefore, if meningococcal sepsis is suspected thephysician should refer to other guidelines specific forrecognizing children/patients with developing shock who needacute sepsis management ( NICE guidelines , ).


Related search queries